Yescar­ta goes to Chi­na as Fo­s­un Kite nabs his­toric first CAR-T OK

The CAR-T era has of­fi­cial­ly ar­rived in Chi­na.

Kite Phar­ma — which had lost out to No­var­tis in the bat­tle for first FDA ap­proval by just two months — can now claim a his­toric first at the Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion, where its joint ven­ture with Fo­s­un steered Yescar­ta to a land­mark OK.

First ac­cept­ed for pri­or­i­ty re­view last March, the CD19-tar­get­ing ther­a­py is in­di­cat­ed for pa­tients with re­lapsed or re­frac­to­ry large B-cell lym­phoma who have re­ceived two or more lines of pri­or treat­ment, ac­cord­ing to an NPMA state­ment. That in­cludes dif­fuse large B-cell lym­phoma and pri­ma­ry me­di­asti­nal large B cell lym­phoma, among oth­ers, they added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.